Key result
Metabolomics studies identified significant alterations in mitochondrial energy, lipid, and amino acid metabolism during anthracycline-induced cardiotoxicity, though little overlap existed between preclinical and clinical studies.
Why the study?
No validated biomarkers currently exist to predict early anthracycline-induced cardiotoxicity, and differences across pre-clinical model systems make translating metabolomics discoveries into clinical development challenging.
Does metabolomic profiling identify early biomarkers of chemotherapy-induced cardiotoxicity in breast cancer models and patients?
Systematic Review (n=27)
Does metabolomic profiling identify early biomarkers of chemotherapy-induced cardiotoxicity in breast cancer models and patients?
Metabolomics reveals significant metabolic alterations in anthracycline-induced cardiotoxicity, highlighting potential early biomarkers and therapeutic targets, though clinical translation remains limited.
Answers are grounded in this paper and cite their sources.
Urgent need for validated early AIC biomarkers persists; leaves open the clinical utility of metabolomics due to pre-clinical model inconsistencies.
Background.While anthracyclines are well known to cause cardiotoxicity, no validated biomarkers that can predict the early development of anthracycline-induced cardiotoxicity (AIC) currently exist. Therefore, early biomarkers of AIC are urgently needed. Metabolomics approaches have been used to elucidate this relationship. However, differences in pre-clinical model systems making it challenging to draw conclusions from the discoveries and translate into clinical development.Aim of Review.A systematic literature review on metabolomics studies of AIC in breast cancer was conducted with the goal to identify and compare study results reported using cell culture models, animal models, tumor-bearing animal models, and clinical patients. We further pooled metabolites identified from all studies to identify biologically meaningful patterns that are significantly enriched in the data. Lastly, pooled metabolites perturbed by AIC were mapped to metabolic pathways for potential pathological implications.Key Scientific Concepts of Review.Altogether, metabolomics studies suggest metabolic alterations in AIC, albeit little overlap between studies especially with breast cancer patients. Attempts at intercepting these pathways have shown that intervention in AIC may be possible. Optimal study design to accurately mimic the human breast cancer condition taking cancer metabolism into consideration will play key role to translate animal models to clinical studies to identify biomarkers in the early diagnosis of AIC and point to new targets for intervention.
No takes yet. Share an insight, caveat, or question.
Bakhtyar et al. (2022) conducted a systematic review in Chemotherapy-induced cardiotoxicity (n=27). Anthracycline-based chemotherapy vs. Control/non-treated was evaluated on Metabolomic biomarkers of cardiotoxicity. Metabolomics studies identified significant alterations in mitochondrial energy, lipid, and amino acid metabolism during anthracycline-induced cardiotoxicity, though little overlap existed between preclinical and clinical studies.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: